国际专家共识:自身免疫病中SSA/Ro(TROVE2/Ro60与TRIM21/Ro52)自身抗体标准化命名建议
该共识基于2000年至2025年的系统文献综述及17位国际专家的Delphi流程,针对SSA/Ro自身抗体命名混乱问题提出标准化建议。经两轮投票,专家组一致推荐使用抗TROVE2/Ro60和抗TRIM21/Ro52抗体这两个术语。
要点
- 推荐使用抗TROVE2/Ro60和抗TRIM21/Ro52抗体作为标准化命名。
- 文献中仅20.9%的研究对两种抗体进行分开检测并报告。
- 抗TROVE2/Ro60有16种、抗TRIM21/Ro52有11种不同命名术语。
核心结论
- 专家组一致推荐在未来的研究和发表中使用抗TROVE2/Ro60和抗TRIM21/Ro52抗体这两个术语。
研究设计与样本
- 系统文献综述纳入2000年1月1日至2025年5月26日发表的SLE和SjD原始研究,经17位国际专家两轮Delphi投票形成共识。
主要发现
- 仅20.9%的研究分开检测并报告两种抗体,75.0%的研究两者均未做,4.2%检测但未分开报告。
- 抗TROVE2/Ro60抗体有16种不同术语,抗TRIM21/Ro52抗体有11种不同术语。
关键数值与推荐
- Delphi专家组经两轮投票一致同意采用抗TROVE2/Ro60和抗TRIM21/Ro52抗体作为推荐术语。
临床怎么用
- 在临床检测和文献发表中应分开报告抗TROVE2/Ro60与抗TRIM21/Ro52抗体,并使用统一术语。
局限性
- 原文未明确报告文献综述和Delphi流程的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Autoantibodies directed against Telomerase RNA Ro y-RNAs and Vault RNAs Domain Family Member 2 (TROVE2)/Ro60 and Tripartite Motif 21 (TRIM21)/Ro52 are historically related to distinct SSA/Ro autoantigens. However, despite advances facilitating separate testing, these autoantibodies remain frequently confused resulting in a lack of clarity and precision in the literature. We conducted a systematic literature review to inform a Delphi process to achieve consensus on a clearer, harmonised nomenclature. METHODS: The systematic review included primary publications in systemic lupus erythematosus (SLE) and Sjögren disease (SjD) published between January 1, 2000 and May 26, 2025 that mentioned testing for anti-TROVE2/Ro60 and/or anti-TRIM21/Ro52 autoantibodies. This analysis contributed to a Delphi consensus exercise proposing preferred nomenclature by a group of 17 international expert physicians and laboratorians. RESULTS: Eight hundred ninety-one publications were included (301 SLE, 493 SjD, and 97 mixed SLE/SjD). Only 20.9% of studies tested and reported the autoantibodies separately; 75.0% did neither; and 4.2% tested but did not report them separately. There was considerable nomenclatural heterogeneity with 16 different terms used for anti-TROVE2/Ro60 and 11 terms for anti-TRIM21/Ro52 autoantibodies. After 2 rounds of voting, the Delphi panel reached a unanimous consensus on the terms anti-TROVE2/Ro60 and anti-TRIM21/Ro52 autoantibodies. CONCLUSIONS: The distinction of anti-TROVE2/Ro60 and anti-TRIM21/Ro52 autoantibodies was frequently unclear and imprecise throughout the literature. Their clinical associations also lacked clarity and precision. To clarify and strengthen the understanding of the clinical associations of these 2 important autoantibodies, the terms anti-TROVE2/Ro60 and anti-TRIM21/Ro52 are recommended for future studies and publications.
引用
- Nikolic RPA, Ben-Chetrit E, Fritzler MJ, et al. International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases. Ann Rheum Dis. 2026. PMID: 42135154. doi:10.1016/j.ard.2026.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。